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Abstract 
Background: The 6-minute walking test (6MWT) is a simple and inexpensive test to establish exercise 
capacity in patients with heart failure. A lower 6MWT distance has been identified as an independent 
predictor of morbidity and mortality in heart failure (HF). However, data on clinical correlates, 
association with treatment up-titration and predictive value of the changes in 6MWT in larger cohorts 
of HF patients are scarce.  
Methods: In BIOSTAT-CHF, a 6MWT was performed both at baseline (n=1,714) and at the 9-month 
visit (n=1,520). Cox-proportional hazards models were used to assess the associations between 
6MWT distance and the primary outcome of death or HF hospitalization and the secondary outcome 
of death. 
Results: The mean±SD 6MWT distance at baseline was 294±130m. Strong and independent 
predictors of a lower 6MWT distance were higher age, female sex, higher heart rate, NYHA III/IV, 
orthopnea, ischemic etiology of HF, a previous stroke, a current malignancy, and higher NT-proBNP 
(all p<0.05). Patients in the lower baseline 6MWT tertile (≤240m) were less frequently treated with 
disease-modifying therapies and were less frequently up-titrated to optimal therapeutic doses (p<0.05 
for both). Compared to patients in the higher baseline 6MWT tertile (>360m), those in the lower and 
intermediate tertiles had worse prognosis: primary outcome adjusted HR (95%CI)=1.73 (1.38-2.18) 
and =1.44 (1.14-1.80), for the lower and intermediate tertiles, respectively. Patients that decreased 
their walking distance from baseline to 9 months had worse prognosis: primary outcome adjusted HR 
(95%CI) per each 50m decrease=1.09 (1.06-1.12). 
Conclusions: 6MWT distance at baseline and a decrease in walking distance were independently 
associated with worse prognosis in HF. These results support the use of the 6MWT to assess patients` 
exercise capacity, prognosis, and as a clinically meaningful end-point in phase II clinical trials. 
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Introduction 
The 6-minute walk test (6MWT) is a simple, reproducible and inexpensive method to assess patients` 
physical capacity1, 2. The 6MWT is sensitive to changes in quality of life and showed a good 
correlation with objective measures of exercise tolerance, such as exercise duration and oxygen 
uptake at the peak of exercise3, 4. Furthermore, some studies showed that the distance walked in the 
6MWT is strongly associated with prognosis in heart failure (HF)5-7. However, only one of these 
reports is derived from an international trial, incorporating a random sample of 898 patients from the 
Studies of Left Ventricular Dysfunction (SOLVD) registry performed two decades ago5. Moreover, 
the prognostic implication of the changes in the 6MWT distance was only assessed in one single 
centre study6.   
The systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-
CHF) is a multicentric international European project designed to determine profiles of patients with 
HF that do or do not respond to recommended therapies, regardless of (anticipated) up-titration8. In 
BIOSTAT-CHF 1,714 HF patients underwent 6MWT both at baseline and 1,520 patients at the 9 
months visit, making the present study the largest to date in studying the association between (change 
in) 6MWT with clinical variables and outcomes in HF. Moreover, the uniqueness of the study design 
also allows to study the association of the 6MWT with the up-titration of guideline-recommended 
therapies. 
The aims of the present study are: 1) to assess the clinical correlates of 6MWT; 2) to ascertain 
the prognostic implications of the 6MWT (both at baseline and change); 3) to study the association 
between the 6MWT distance with the up-titration of ACE-inhibitors/ARBs and beta-blockers. 
 
Methods 
Patient population  
BIOSTAT-CHF is a European project that enrolled 2,516 HF patients from 69 centres in 11 
European countries to determine profiles of patients with HF who not respond to recommended 
therapies, despite anticipated up-titration. The design and first results of the study and patients have 
been described elsewhere8. Briefly, patients were aged ≥18 years with signs and symptoms of 
worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or a BNP 
and/or NT-proBNP plasma levels >400 pg/mL and/or >2000 pg/mL, respectively. Patients needed to 
be treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of 
inclusion. Patients should not have been previously treated with evidence-based therapies 
(ACEi/ARBs and beta-blockers) or were receiving <50% of the target doses of at least one of these 
drugs at the time of inclusion9, 10. The first three months of treatment were considered to be the 
optimization phase after which a stabilization phase of 6 months was defined. During the optimization 
phase, initiation or up-titration of ACEi/ARB and/or β-blocker was performed according to the 
routine clinical practice of the treating physicians, who were encouraged to follow the ESC guidelines 
at the time of treatment9, 10. Patients reaching at least 50% of the recommended dose of ACEi/ARB 
and/or β-blocker were considered successfully up-titrated. 
The recruitment period was 24 months, starting from December 2010. The last patient was 
included on December 15, 2012. Median follow-up was 21 months. Ethics Board approval was 
obtained and all participants signed written informed consent before entering the study.  
The BIOSTAT-CHF risk models used for adjustment throughout these analyses have been 
previously developed and validated11.  
6-Minute Walking Test 
The 6MWT was performed in a long, straight hospital corridor, over a 30-m distance. Each participant 
was asked to walk (not run) back and forth along the corridor as briskly as possible, so that the longest 
possible distance was covered in six minutes. The participant was allowed to slow down or stop and 
rest if necessary, particularly in the case of symptoms such as severe dyspnoea or fatigue. During any 
rest period, the participant was informed of the elapsed time and encouraged to recommence walking 
when the symptoms attenuated enough to allow walking. However, the test was discontinued if the 
symptoms persisted. The participant was also allowed to discontinue the test at will at any time. 
Moreover, the test was interrupted by the investigator immediately one of the following symptoms 
appeared: chest pain that did not resolve at rest, dyspnoea precluding continuation of walking, cramps 
of the lower limb muscles, balance difficulty, severe sweating, pallor, or cyanosis. Otherwise, every 
two minutes during the test, an investigator informed the participant of the amount of time left and 
encouraged him to continue the test. At six minutes, the participant was advised to stop and be seated. 
The distance walked was measured to the nearest whole metre. The procedure was standardized 
across centres i.e., consistent 6MW test methodology was specified in the BIOSTAT-CHF manual of 
operations, including standardized phrasing (e.g., “cover as much ground as possible… keep going… 
don’t worry if you have to sit down or stop to rest…”) and consistent timing of encouragement (1-
minute intervals). 802 patients did not perform the 6MWT – the characteristics of these patients and 
the reasons for not performing the test are described in the Supplemental Table 1. 
Statistical analysis 
Population description and comparison of outpatients vs. inpatients was performed using t-test, Mann-
Whitney or chi-square test, as appropriate.  
Cox proportional hazard regression models were used to model long-term event rate of the 
variables included in the previously published BIOSTAT-CHF risk models11. Proportional hazard 
assumption was verified graphically using "log-log" plots. Log-linearity was checked by testing the 
functional forms of the covariable by the Kolmogorov-type supremum test and by visual inspection 
by plotting the beta estimates versus the mean across quintiles. No multiple imputation was 
performed.  The covariates used for adjustment when assessing the hazard ratio associated with the 
6MWT distance were chosen from demographic (age and sex), clinical (previous HF hospitalization, 
use of beta-blockers and systolic blood pressure), and laboratory (NT-proBNP, blood urea nitrogen, 
hemoglobin, HDL-cholesterol, estimated glomerular filtration rate [eGFR] by the CKD-EPI formula12, 
13, and sodium). All these variables were previously found to be independently associated with the 
outcomes in the BIOSTAT-CHF cohort and were the variables used to build the risk models depicted 
herein (URL: https://biostat-chf.shinyapps.io/calc/)11. For visualization purposes, the relationship 
between 6MWT and the log-hazard of outcome was also assessed using restricted cubic splines with 3 
knots located to the 10th, 50th and 90th percentiles according to the Harrell rule14. The adjusted 
changes (delta) in the walking distance were calculated by the 6MWT distance at month 9 minus the 
6MWT distance at baseline adjusted on the baseline 6MWT distance. For the study of 6MWT 
distance changes between baseline and 9 months, the time-to-event was set at the 9-month visit and 
non-fatal outcomes before the 9-month visit were censored (“landmark analysis”). 
The primary outcome was a composite of HF hospitalization and all-cause death. All-cause 
death was also assessed separately as exploratory outcome. The adjudication of events (heart failure 
hospitalizations) were done by the treating physician. 
All the analyses were performed using STATA (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). A p-value <0.05 was considered as statistically 
significant. 
 
Results 
Characteristics of the study population 
Of a total of 2,516 patients, the 6MWT was performed at baseline in 1,714 and at the 9-month visit in 
1,520 patients. The comparison of those who performed vs. those who did not perform the 6MWT is 
depicted in the Supplemental Table 1. The 802 patients who did not perform 6MWT were older, 
more often female, inpatients, had higher BMI, heart rate, congestive signs and symptoms, had lower 
blood pressure, had been more often hospitalized in the previous year, had higher proportion of 
stroke, peripheral vascular disease history and cancer, had lower hemoglobin, eGFR, sodium and 
potassium levels, had higher NT-proBNP and troponin levels, and were less often treated with beta-
blockers and ACEi/ARBs. Most of these patients had no specific reason for not performing 6MWT 
written in the CRF but they were clearly in poorer “health status” and more often hospitalized 
compared to those who did perform the test. Supplemental Table 1 (legend).    
Compared to the intermediate (241-360m) and the higher (>360m) 6MWT distance tertiles, 
patients in the lower tertile (≤240m) were older, more often female, more often observed as inpatients, 
had higher heart rate, more congestive signs and symptoms, more often HF of ischemic etiology, 
previous HF hospitalization, atrial fibrillation, peripheral artery disease, and COPD, had lower 
hemoglobin levels, worse renal function, higher NT-proBNP and troponin levels and were less often 
up-titrated with regards to ACEi/ARBs and beta-blockers (all p<0.05 for trend). Table 1 for baseline 
and Supplemental Table 2 for the 9-month visit. 
 
6MWT and its clinical correlates 
Older age, higher heart rate, in-hospital treatment, congestive symptoms, HF of ischemic etiology, 
previous stroke, cancer, and higher values of NT-proBNP and troponin I were all independent and 
negatively associated with 6MWT distance, whereas male sex and higher sodium levels were 
positively associated. Table 2 for baseline and Supplemental Table 3 for the 9-month visit. 
 
Prognostic associations 
The 6MWT distance was linearly associated with the study outcomes: for each 50m less in the 6MWT 
distance, patients had an adjusted 8% increment in the risk for HF hospitalization or death and 14% 
increased risk for death. Table 3 & Figure 1. Compared to patients walking more than 360m, those 
walking between 241 and 360m and those walking 240m or less had increased rates of all outcome 
events: adjusted HR (95%CI) for the primary outcome of HF hospitalization or death =1.44 (1.14-
1.80) and 1.73 (1.38-2.18), respectively. Table 3. Similar results were found for the 9-month visit. 
Supplemental Table 4. The 6MWT did not improve the discrimination (c-index) of the BIOSTAT 
prognostic models (c-index =0.71 for the primary outcome and 0.73 for death). 
 Patients who decreased their walking distance from baseline to the 9-month visit also had 
worse prognosis in a linear fashion: HR (95%CI) =1.09 (1.06-1.12) per each 50m decrease for the 
primary outcome. Table 6 & Figure 2. Older patients, those with diabetes and higher NT-proBNP 
values were less likely to improve their walking distance. Supplemental Tables 5 & 6. The 
distribution of the baseline and the changes in the walked distance is represented in the Supplemental 
Figure 1 & 2. 
 
Comparison with other common risk factors 
Patients walking 240m or less had worse prognosis than those aged above 75, those with diabetes, 
atrial fibrillation, severe renal impairment, COPD or previous stroke. Figure 3.  
 
Association with treatment up-titration 
Patients walking shorter distances in the 6MWT were less likely to be up-titrated above 50% of the 
recommended doses of ACEi/ARBs and beta-blockers. Table 4. However, up-titration of ACEi/ARBs 
and/or beta-blockers was not associated with changes in the walking distance. Table 5. 
 
Discussion 
Our study shows that patients who walked shorter distances in the 6MWT were older, had more co-
morbid conditions, were more often treated as inpatients and had higher natriuretic peptide levels. In 
particular, older age, hospitalization, higher heart rate, congestive signs and symptoms, HF of 
ischemic etiology, previous stroke, cancer, and higher values of NT-proBNP and troponin I were all 
negatively associated with 6MWT distance, whereas male sex and higher sodium levels were 
positively associated. The 6MWT distance had a linear association with the studied outcomes i.e. the 
less patients walked the worse their prognosis (19% event-rate increase per each 50m less for the 
baseline 6MWT distance) and a decrease the walked distance from baseline visit to the 9-month visit 
was also associated with worse subsequent outcomes (9% event-rate increase per each 50m decrease 
between visits). Patients who walked shorter distances were also less likely to be up-titrated on ACE-
inhibitors/ARBs and beta-blockers. The present study is relevant in several aspects: 1) it is 
contemporary, multicentric, and international; 2) assesses the clinical correlates of 6MWT; 3) 
identifies the prognostic associations of 6MWT at baseline and also the changes between two time-
points and subsequent outcomes; 4) compares the prognostic associations of the 6MWT with those of 
common clinical conditions such as diabetes and atrial fibrillation; 5) it is also the first to study the 
association between 6MWT and HF treatment up-titration.  From a clinical standpoint, the present 
study provides insight on the use of this simple and inexpensive text. In routine practice, performing a 
6MWT provides relevant prognostic information and an objective assessment of patients` exercise 
capacity, allowing close monitorization of the clinical course of the disease.  
The 6MWT is performed by asking the patient to walk the longest distance possible in a 6-
minute interval through a walking corridor (preferably 30m long). The patient can stop or slow down 
at any time and then resume walking, depending on the degree of fatigue1. Even though other 
variables can be monitored during the test (e.g. blood pressure, oxygen saturation and/or heart rate), 
the distance walked is the parameter that has proven to be most useful in nearly all clinical studies1. 
The association of the 6MWT distance with morbidity and mortality is not surprising since the 6MWT 
is itself a reflection of exercise tolerance, limited by several non-cardiovascular factors such as 
conditioning, osteoarticular pathology, patient effort and willingness/motivation to perform the test. In 
addition, the 6MWT (and other exercise parameters) also rely on the ability of skeletal muscle to 
extract oxygen from blood, pulmonary and endothelial function, and cardiac output15. Moreover, the 
6MWT is likely to perform better (as prognostic tool) in patients with severe and symptomatic HF 
(like those enrolled in the BIOSTAT-CHF) whose 6MWT is most severely limited and an 
improvement could be clinically  meaningful16.  
In the SOLVD trial5, a stratified random sample of 898 patients with symptomatic HF and an 
ejection fraction ≤45% or less underwent a 6MWT. During a mean follow-up of 8 months 52 (6%) 
patients died and 252 (30%) were hospitalized. Compared with those walking at least 450m, patients 
walking less than 300m had higher event rates. Smaller observational studies with assessment of 
baseline 6MWT also demonstrated an independent association between the walked distance and 
mortality in patients with systolic dysfunction5, 7, 16.  An analysis from the HF-ACTION trial including 
2,054 HF patients also showed that a shorter walked distance in the baseline 6MWT was associated 
with worse outcomes17. The association between the changes in the walked distance between two 
visits and subsequent outcome was analysed in a single centre study with 600 HF patients followed 
for 8 years6. In this study, a decrease in the 6MWT distance from the baseline visit to the 1-year visit 
was independently associated with increased death rates6. To the best of our knowledge our study is 
the first contemporary multicentric and international study to study the association between the 
changes in the 6MWT distance between two time-point and subsequent outcomes. The demonstration 
that older patients, diabetics and those with higher natriuretic peptide values were less likely to 
improve the distance walked and that a decrease in the 6MWT distance is associated with worse 
subsequent outcomes in a linear fashion suggests that we may identify the patients more prone to 
decrease the distance walked and that any deterioration in the 6MWT distance may be of clinical 
significance. 
In the present study a lower 6MWT distance was also associated with lower proportion of 
treatment up-titration. However, treatment up-titration was not associated with changes in the 6MWT 
distance. In should be noted that the 6MWT distance improved in the majority of trials of cardiac 
resynchronization therapy but showed inconsistent results in pharmacologic (such as ACE-inhibitors 
and beta-blockers) and device (such as vagus nerve stimulation) trials18. 
6MWT as a clinically meaningful endpoint 
The 6MWT is an inexpensive and reproducible method to assess exercise tolerance that can be 
performed in the majority of HF patients (even when exercise capacity in limited by severity of 
disease or multiple co-morbidities). The 6MWT can be applied in the setting of a RCT and is itself a 
clinically meaningful endpoint i.e. it is associated with clinical status, quality of life, and capacity to 
perform activities of daily living. Therefore, the 6MWT can be used in phase II trials and is also a 
good surrogate for “hard” clinical endpoints in phase III trials (as supported by the present study). 
Cardiopulmonary exercise testing (CPX) is an evidence-based relevant tool for risk stratification and 
prognosis in HF19. However, CPX requires specific equipment and personnel adequately trained in the 
performance and interpretation of the test20, making CPX a complex procedure to be widely applied in 
the setting of a RCT. Moreover, results of the 6MWT show good correlation with exercise capacity 
measured by formal treadmill and CPX5, 21. In general, a 30-50m increase in 6MWT distance is 
considered a clinically significant improvement, is associated with a significant improvement in 
NYHA class and health related quality of life and has been used in the “device” trials as relevant to 
pre-market approval22-25. 
In resume, the 6MWT can be used as end-point per se, and if aligned with other measures 
(such as natriuretic peptides and imaging) it is associated with morbidity and mortality in HF18. 
 
Limitations 
 Several limitations should be acknowledged in this analysis. First, this is a post-hoc analysis 
of a prospective non-randomized observational study, therefore all limitations inherent to such 
analysis are applied herein, including the inability to infer causality. Second, the data from the 
BIOSTAT-CHF come from European centres only and may not be representative of HF patients in 
other world regions. Third, all patients enrolled in the BIOSTAT-CHF had severe symptoms and high 
natriuretic peptide levels, hence these findings cannot be generalized to less symptomatic HF patients.  
 
Conclusion 
The 6MWT distance at baseline and a decrease in the walked distance in a 9-month period were 
independently associated with worse prognosis in HF in a linear fashion. Patients with lower walked 
distance were also less likely to have their HF treatments up-titrated, but treatment up-titration did not 
improve the distance walked. These results support the use of the 6MWT to assess patients` exercise 
capacity, prognosis, and could be used as a clinically meaningful end-point in phase II clinical trials. 
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Figure 1. Spline for the association of baseline 6MWT with regards to the primary outcome  
 
Legend: 6MWT, 6-minute walking test distance; X-axis, distance in meters x 50 (1 =50m; 5 
=250m;10 =500m). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Spline for the association of the delta 6MWT with regards to the primary outcome  
 
Legend: 6MWT, 6-minute walking test distance; X-axis, distance in meters x 50 (5 =250m;10 
=500m). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Forest plot comparing the primary outcome event rates associated with 6MWT with those of 
common risk factors in HF 
 
Legend: 6MWT, 6-minute walking test; Afib, atrial fibrillation; COPD, chronic obstructive 
pulmonary disease; HF, heart failure; eGFR, estimated glomerular filtration rate. 
Table 1. Characteristics of the study population by baseline 6MWT tertiles 
6MWT (tertiles) ≤240 m  241-360 m >360 m p-value 
N. 591 586 537  
Age (years) 73.2 ± 10.1 67.0 ± 11.5 62.3 ± 11.2 <0.001 
Male sex 374 (63.3%) 453 (77.3%) 465 (86.6%) <0.001 
Inpatient visit 391 (66.2%) 329 (56.1%) 252 (46.9%) <0.001 
BMI (Kg/m2) 27.8 ± 5.4 27.5 ± 4.9 27.7 ± 4.8 0.68 
Heart rate (bpm) 82.2 ± 19.4 78.5 ± 18.7 78.9 ± 20.9 0.002 
SBP (mmHg) 125.4 ± 21.2 125.1 ± 20.1 125.6 ± 20.3 0.92 
Pulmonary rales 345 (59.2%) 278 (48.5%) 157 (30.3%) <0.001 
Peripheral edema 343 (68.2%) 271 (55.2%) 167 (39.2%) <0.001 
Elevated JVP 127 (32.6%) 95 (23.2%) 72 (18.6%) <0.001 
NYHA class III/IV 421 (72.3%) 312 (54.4%) 203 (38.1%) <0.001 
Orthopnea  196 (33.3%) 150 (25.6%) 105 (19.6%) <0.001 
LVEF (%) 32.3 ± 11.1 30.0 ± 10.1 29.9 ± 8.5 <0.001 
Ischemic HF 295 (49.9%) 256 (43.7%) 195 (36.3%) <0.001 
PCI or CABG 223 (37.7%) 192 (32.8%) 151 (28.1%) 0.003 
HFH in the last 12 months 228 (38.6%) 193 (32.9%) 162 (30.2%) 0.009 
Atrial fibrillation 299 (50.6%) 246 (42.0%) 217 (40.4%) <0.001 
Previous stroke 61 (10.3%) 40 (6.8%) 33 (6.1%) 0.018 
Peripheral arterial disease 73 (12.4%) 42 (7.2%) 45 (8.4%) 0.006 
Hypertension 404 (68.4%) 380 (64.8%) 307 (57.2%) <0.001 
Device therapy 151 (25.5%) 133 (22.7%) 113 (21.0%) 0.19 
Current smoking 73 (12.4%) 78 (13.3%) 80 (14.9%) 0.005 
Diabetes 238 (40.3%) 173 (29.5%) 132 (24.6%) <0.001 
COPD 138 (23.4%) 90 (15.4%) 64 (11.9%) <0.001 
Malignancy 25 (4.2%) 15 (2.6%) 9 (1.7%) 0.032 
Hemoglobin (g/dL) 12.7 ± 1.8 13.3 ± 1.8 13.9 ± 1.6 <0.001 
eGFR (ml/min/1.73m2) 56.9 ± 21.5 64.8 ± 23.6 72.3 ± 21.1 <0.001 
Urea (mmol/L) 15.8 ± 10.3 13.3 ± 10.8 12.2 ± 8.8 <0.001 
Sodium (mmol/L) 139.1 ± 4.1 139.4 ± 3.5 140.0 ± 3.1 <0.001 
Potassium (mmol/L) 4.2 ± 0.6 4.2 ± 0.5 4.3 ± 0.5 0.66 
Glucose (mmol/L) 7.2 ± 3.1 6.9 ± 2.9 6.7 ± 2.4 0.047 
Total cholesterol (mmol/L) 4.1 ± 1.37 4.4 ± 1.3 4.5 ± 1.2 <0.001 
HDL cholesterol (mmol/L) 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.3 0.52 
NT-pro BNP (NPX) 3.3 ± 1.3 2.7 ± 1.3 2.4 ± 1.1 <0.001 
Log10 TnI (pg/mL) 1.2 ± 0.5 1.1 ± 0.5 0.9 ± 0.5 <0.001 
MRA 289 (48.9%) 327 (55.8%) 302 (56.2%) 0.019 
Loop diuretics 590 (99.8%) 582 (99.3%) 534 (99.4%) 0.40 
Digoxin 110 (18.6%) 108 (18.4%) 102 (19.0%) 0.97 
Beta-blocker  475 (80.4%) 513 (87.5%) 465 (86.6%) 0.001 
Beta-blocker >=50% at 3 mo. 196 (33.2%) 222 (37.9%) 223 (41.5%) 0.014 
ACEi/ARB  408 (69.0%) 449 (76.6%) 418 (77.8%) 0.001 
ACEi/ARB >=50% at 3 mo. 282 (47.7%) 324 (55.3%) 342 (63.7%) <0.001 
6MWT (meters)  147.8 ± 62.8 307.0 ± 34.7 439.4 ± 61.9 - 
Legend: BMI, body mass index; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting; HFH, heart failure hospitalization; COPD, chronic 
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; 
ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
Table 2. Multivariable linear regression for baseline 6MWT (m) as dependent variable  
Continuous 6MWT (baseline) Std. beta-coefficient Std. Err. P-value 
Age (per 10 yr) -33.0 (-39.2 to -26.7) 3.2 <0.001 
Male sex 59.2 (43.1 to 75.3) 8.2 <0.001 
Inpatient -68.4 (-85.6 to -51.2) 8.8 <0.001 
Heart rate (per 10 bpm) -6.1 (-9.5 to -2.7) 1.7 <0.001 
NYHA III/IV -58.9 (-75.2 to -42.6) 8.3 <0.001 
Orthopnea -31.5 (-47.6 to -15.4) 8.2 <0.001 
Ischemic heart failure -32.8 (-47.3 to -18.3) 7.4 <0.001 
Previous stroke -37.2 (-60.6 to -13.7) 11.9 0.002 
Current malignancy -46.2 (-83.9 to -8.6) 19.2 0.016 
Sodium (per 1 mmol/L) 4.0 (2.3 to 5.7) 0.9 <0.001 
NT-proBNP (per NPX doubling) -12.4 (-18.0 to -6.9) 2.8 <0.001 
LogTnI (per each Log10) -28.8 (-42.2 to -15.5) 6.8 <0.001 
Model adjusted R2 =0.35 
Constant = 147.6 
The standardized (std.) beta-coefficient compares the strength of the effect of each individual independent variable to the 
dependent variable (6MWT). The higher the absolute value of the beta coefficient, the stronger the effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Cox-proportional hazards models for baseline 6MWT 
HFH or Death N. (%) of events Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
Continuous 6MWT (m) 
Per each 50m less 641 (37.4%) 1.19 (1.15-1.22) <0.001 1.08 (1.04-1.11) <0.001 
Tertile 6MWT (m) 
>360 m 118 (22.0%) Reference - Reference - 
241-360 m 210 (35.8%) 1.85 (1.47-2.31) <0.001 1.44 (1.14-1.80) 0.002 
≤240 m  313 (53.0%) 3.07 (2.48-3.79) <0.001 1.73 (1.38-2.18) <0.001 
Death N. (%) of events Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
Continuous 6MWT (m) 
Per each 50m less 385 (22.5%) 1.25 (1.19-1.30) <0.001 1.14 (1.09-1.18) <0.001 
Tertile 6MWT (m) 
>360 m 57 (10.6%) Reference - Reference - 
241-360 m 109 (18.6%) 1.88 (1.37-2.60) <0.001 1.49 (1.08-2.06) 0.016 
≤240 m  219 (37.1%) 4.11 (3.08-5.50) <0.001 2.41 (1.76-3.29) <0.001 
*Adjusted on the BIOSTAT-CHF risk model including: age, heart failure hospitalizations in previous year, systolic blood 
pressure, presence of peripheral edema, NT-proBNP, hemoglobin, sodium, HDL cholesterol, and the use of beta-blockers 
(https://biostat-chf.shinyapps.io/calc/). 
Total n. =1,714; Tertile n. ≤240m =591; 241-360m =586; >360m =537. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Logistic regression for 6MWT as treatment up-titration determinant 
Treatment up-titration OR (95%CI)* p-value 
ACEi/ARB or β-blocker ≥50% 
Continuous 6MWT (m) 
6MWT per each 50m less 0.91 (0.85-0.97) 0.002 
Tertile 6MWT (m) 
>360 m Reference - 
241-360 m 0.66 (0.47-0.92) 0.014 
≤240 m  0.63 (0.43-0.92) 0.016 
ACEi/ARB ≥50% 
Continuous 6MWT (m) 
6MWT per each 50m less 0.95 (0.90-1.01) 0.052 
Tertile 6MWT (m) 
>360 m Reference - 
241-360 m 0.76 (0.56-1.02) 0.075 
≤240 m  0.75 (0.54-1.04) 0.088 
β-blocker ≥50% 
Continuous 6MWT (m) 
6MWT per each 50m less 0.91 (0.85-0.96) 0.001 
Tertile 6MWT (m) 
>360 m Reference - 
241-360 m 0.85 (0.63-1.16) 0.31 
≤240 m  0.66 (0.46-0.94) 0.022 
*Adjusted on the “best” up-titration prediction model including: age, sex, race, heart failure duration, heart failure 
hospitalization in the previous year, heart failure of ischemic etiology, diabetes mellitus, hypertension, body mass index, 
systolic blood pressure, heart rate, left ventricular ejection fraction, NT-pro BNP, estimated glomerular filtration rate,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Logistic and linear regression for the association of medication up-titration with 6MWT 
change in meters (from baseline to 9-months)  
Logistic regression for 6MWT change as categorical variable 
Up-titration 6MWT decrease 6MWT increase OR (95%CI) P-value 
ACEi/ARB or BB ≥50% 339 (71.8%) 889 (71.3%) 0.97 (0.77-1.23) 0.83 
ACEi/ARB ≥50% 266 (56.4%) 705 (56.5%) 1.01 (0.81-1.25) 0.95 
Beta-blocker ≥50% 200 (42.4%) 497 (39.9) 0.90 (0.73-1.12) 0.34 
Linear regression for 6MWT change as continuous variable 
Up-titration 6MWT change : beta coefficient (95%CI) Std. error P-value 
ACEi/ARB or beta-blocker ≥50% 4.42 (-13.78 to 22.63) 9.28 0.63 
ACEi/ARB ≥50% 2.78 (-13.80 to 19.37) 8.46 0.74 
Beta-blocker ≥50% -7.21 (-23.95 to 9.53) 8.54 0.40 
Legend: 6MWT, 6-minute walking test distance in meters; ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin 
receptor blocker. 
The standardized beta-coefficient compares the strength of the effect of each individual independent variable to the 
dependent variable (6MWT). The higher the absolute value of the beta coefficient, the stronger the effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Cox-proportional hazards models 6MWT distance increase from baseline to 9 months 
HFH or Death Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
Per each 50m decrease (continuous) 1.09 (1.06-1.12) <0.001 1.09 (1.06-1.12) <0.001 
6MWT (decrease vs. increase) 1.56 (1.30-1.85) <0.001 1.54 (1.30-1.85) <0.001 
Death Crude HR (95%CI) P-value Adjusted HR (95%CI)* P-value 
Per each 50m decrease (continuous) 1.09 (1.04-1.14) <0.001 1.09 (1.04-1.14) <0.001 
6MWT (decrease vs. increase) 1.59 (1.20-2.08) <0.001 1.64 (1.25-2.13) <0.001 
*Adjusted on the BIOSTAT-CHF risk model including: age, heart failure hospitalizations in previous year, systolic blood 
pressure, presence of peripheral edema, NT-proBNP, hemoglobin, sodium, HDL cholesterol, and the use of beta-blockers 
(https://biostat-chf.shinyapps.io/calc/). 
 
Supplemental Table 1. comparing those who did 6MWT with those who did not 
6MWT Missing Non-missing p-value 
N. 802 1,714  
Age (years) 69.9 ± 12.1 67.6 ± 11.8 <0.001 
Male sex 554 (69.1%) 1292 (75.4%) <0.001 
Inpatients 722 (90.0%) 80 (10%) <0.001 
BMI (Kg/m2) 28.4 ± 6.3 27.7 ± 5.1 0.004 
Heart rate (bpm) 87.3 ± 23.8 79.9 ± 19.7 <0.001 
SBP (mmHg) 123.3 ± 24.5 125.4 ± 20.6 0.026 
Pulmonary rales 511 (66.3%) 780 (46.6%) <0.001 
Peripheral edema 475 (70.0%) 781 (55.0%) <0.001 
Elevated JVP 260 (45.9%) 294 (24.8%) <0.001 
NYHA class III/IV 586 (77.4%) 936 (55.4%) <0.001 
Orthopnea  428 (53.5%) 451 (26.4%) <0.001 
LVEF (%) 31.7 ± 11.9 30.7 ± 10.0 0.056 
Ischemic HF 357 (44.5%) 746 (43.5%) 0.24 
PCI or CABG 276 (34.4%) 566 (33.0%) 0.49 
HFH in the last 12 months 211 (26.3%) 583 (34.0%) <0.001 
Atrial fibrillation 381 (47.5%) 762 (44.5%) 0.15 
Previous stroke 99 (12.3%) 134 (7.8%) <0.001 
Peripheral arterial disease 113 (14.1%) 160 (9.3%) <0.001 
Hypertension 478 (59.6%) 1091 (63.7%) 0.051 
Device therapy 221 (27.6%) 397 (23.2%) 0.017 
Current smoking 122 (15.3%) 231 (13.5%) 0.49 
Diabetes 276 (34.4%) 543 (31.7%) 0.17 
COPD 144 (18.0%) 292 (17.0%) 0.57 
Malignancy 48 (6.0%) 49 (2.9%) <0.001 
Hemoglobin (g/dL) 12.9 ± 1.9 13.3 ± 1.8 <0.001 
eGFR (ml/min/1.73m2) 58.1 ± 23.2 64.4 ± 22.9 <0.001 
Urea (mmol/L) 16.8 ± 14.0 13.8 ± 10.1 <0.001 
Sodium (mmol/L) 138.4 ± 4.4 139.5 ± 3.7 <0.001 
Potassium (mmol/L) 4.2 ± 0.5 4.3 ± 0.6 <0.001 
Glucose (mmol/L) 7.5 ± 3.3 6.9 ± 2.9 <0.001 
Total Cholesterol (mmol/L) 4.0 ± 1.3 4.3 ± 1.3 <0.001 
HDL (mmol/L) 1.1 ± 0.4 1.1 ± 0.4 0.14 
NT-pro BNP (NPX) 3.4 ± 1.4 2.8 ± 1.3 <0.001 
Log10 TnI (pg/mL) 1.3 ± 0.5 1.1 ± 0.6 0.002 
MRA 421 (52.5%) 918 (53.6%) 0.62 
Loop diuretics 798 (99.5%) 1706 (99.5%) 0.91 
Digoxin 171 (21.3%) 320 (18.7%) 0.12 
Beta-blocker  640 (79.8%) 1453 (84.8%) 0.002 
Beta-blocker >=50% at 3 mo. 261 (32.5%) 641 (37.4%) 0.018 
ACE/ARB  545 (68.0%) 1275 (74.4%) <0.001 
ACE/ARB >=50% at 3 mo. 364 (45.4%) 948 (55.3%) <0.001 
6MWT (meters)  - 293.6 ± 130.5 - 
Legend: BMI, body mass index; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting; HFH, heart failure hospitalization; COPD, chronic 
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; 
ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
Of the 802 patients who did not perform the 6MWT, 710 (89%) had no specific reason written in the CRF, the following 
reasons were “not a routine” (n=7; 0.9%) and “no time” (n=6; 0.8%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 2. Characteristics of the study population by 9-month 6MWT tertiles 
6MWT (tertiles) ≤240 m 241-396 m >396 m p-value 
N. 510 505 505  
Age (years) 73.3 ± 10.4 69.0 ± 10.5 61.5 ± 11.5 <0.001 
Male sex 392 (63.8%) 433 (76.8%) 495 (84.0%) <0.001 
BMI (Kg/m2) 28.1 ± 6.1 28.1 ± 5.5 27.8 ± 4.9 0.44 
Heart rate (bpm) 73.8 ± 14.3 72.3 ± 15.4 69.8 ± 13.2 <0.001 
SBP (mmHg) 124.4 ± 22.3 124.1 ± 19.4 125.9 ± 19.9 0.25 
Pulmonary rales 84 (16.2%) 52 (10.0%) 17 (3.2%) <0.001 
Peripheral edema 195 (36.9%) 104 (21.6%) 45 (9.3%) <0.001 
Elevated JVP 60 (15.0%) 27 (6.6%) 12 (2.8%) <0.001 
NYHA class III/IV 303 (50.8%) 106 (18.9%) 33 (5.6%) <0.001 
Orthopnea  120 (19.7%) 39 (7.0%) 15 (2.6%) <0.001 
LVEF (%) 34.9 ± 11.7 33.8 ± 10.5 36.8 ± 10.5 0.002 
Ischemic HF 299 (48.7%) 247 (43.8%) 203 (34.5%) <0.001 
Atrial fibrillation 310 (50.5%) 227 (40.2%) 224 (38.0%) <0.001 
Previous stroke 74 (12.1%) 47 (8.3%) 36 (6.1%) 0.001 
Peripheral arterial disease 87 (14.2%) 49 (8.7%) 30 (5.1%) <0.001 
Hypertension 426 (69.4%) 365 (64.7%) 309 (52.5%) <0.001 
Device therapy 166 (27.0%) 134 (23.8%) 113 (19.2%) 0.005 
Current smoking 82 (13.4%) 72 (12.8%) 96 (16.3%) 0.14 
Diabetes 240 (39.1%) 193 (34.2%) 114 (19.4%) <0.001 
COPD 118 (19.2%) 102 (18.1%) 67 (11.4%) <0.001 
Malignancy 32 (5.2%) 15 (2.7%) 12 (2.0%) 0.005 
Hemoglobin (g/dL) 12.6 ± 1.7 13.2 ± 1.6 13.8 ± 1.5 <0.001 
eGFR (ml/min/1.73m2) 59.3 ± 24.7 67.0 ± 23.4 77.5 ± 22.4 <0.001 
Urea (mmol/L) 15.4 ± 10.7 12.6 ± 9.7 11.3 ± 7.4 <0.001 
Sodium (mmol/L) 138.9 ± 3.8 139.3 ± 3.2 139.7 ± 2.9 0.003 
Potassium (mmol/L) 4.4 ± 0.5 4.4 ± 0.5 4.3 ± 0.4 0.054 
Glucose (mmol/L) 7.1 ± 3.4 6.5 ± 2.4 6.3 ± 2.1 0.003 
NT-pro BNP (NPX) 3.1 ± 1.3 2.7 ± 1.2 2.5 ± 1.2 <0.001 
Log10 TnI (pg/mL) 1.2 ± 0.5 1.1 ± 0.5 1.0 ± 0.5 <0.001 
MRA 335 (54.7%) 355 (63.1%) 358 (60.8%) 0.011 
Loop diuretics 448 (73.0%) 424 (75.2%) 429 (72.8%) 0.60 
Digoxin 131 (21.3%) 104 (18.4%) 88 (14.9%) 0.016 
Beta-blocker >=50% 224 (36.5%) 213 (37.8%) 246 (41.8%) 0.15 
ACE/ARB >=50%  302 (49.2%) 317 (56.2%) 382 (64.9%) <0.001 
6MWT (m) 93.8 ± 91.5 325.9 ± 42.2 486.4 ± 75.6 - 
Legend: BMI, body mass index; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting; HFH, heart failure hospitalization; COPD, chronic 
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; 
ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
 
 
 
 
 
 
Supplemental Table 3. Multivariable linear regression for 9-month 6MWT as dependent variable 
6MWT (9 months) Std. beta-coefficient Std. Err. P-value 
Age (per 10 yr) -47.5 (-55.9 to -39.2) 4.2 <0.001 
Male sex 56.5 (35.4 to 77.7) 10.7 <0.001 
Peripheral edema -60.9 (-83.6 to -38.1) 11.6 <0.001 
NYHA III/IV -107.1 (-130.4 to -83.9) 11.8 <0.001 
Orthopnea -39.7 (-71.9 to -7.5) 16.4 0.016 
Peripheral artery disease -59.7 (-90.3 to -29.1) 15.5 <0.001 
Diabetes -36.7 (-56.9 to -16.4) 10.3 <0.001 
Sodium (per 1 mmol/L) 3.0 (0.3 to 5.7) 1.4 0.027 
NT-proBNP (per NPX doubling) -13.5 (-20.6 to -6.3) 3.6 <0.001 
Model adjusted R2 =0.38 
Constant =253.4 
The standardized beta-coefficient compares the strength of the effect of each individual independent variable to the 
dependent variable (6MWT). The higher the absolute value of the beta coefficient, the stronger the effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 4. Cox-proportional hazards models for 9-month 6MWT 
HFH or Death N. (%) events Crude HR 
(95%CI) 
P-value Adjusted HR 
(95%CI)* 
P-value 
Per each 50m less 411 (27.0%) 1.17 (1.15-1.20) <0.001 1.12 (1.09-1.15) <0.001 
>396 m 74 (14.7%) Reference - Reference - 
241-396 m 108 (21.4%) 1.83 (1.41-2.37) <0.001 1.42 (1.08-1.84) 0.010 
≤240 m   229 (44.9%) 3.86 (3.05-4.87) <0.001 2.53 (1.98-3.23) <0.001 
Death N. (%) events Crude HR 
(95%CI) 
P-value Adjusted HR 
(95%CI)* 
P-value 
Per each 50m less 164 (10.8%) 1.21 (1.17-1.26) <0.001 1.16 (1.12-1.20) <0.001 
>396 m 22 (4.4%) Reference - Reference - 
241-396 m 45 (8.9%) 2.63 (1.66-4.15) <0.001 2.08 (1.31-3.31) 0.002 
≤240 m   97 (19.0%) 5.87 (3.87-8.91) <0.001 3.87 (2.51-5.98) <0.001 
*Adjusted on the BIOSTAT-CHF risk model including: age, heart failure hospitalizations in previous year, systolic blood 
pressure, presence of peripheral edema, NT-proBNP, hemoglobin, sodium, HDL cholesterol, and the use of beta-blockers 
(https://biostat-chf.shinyapps.io/calc/). 
Total n. =1,520; Tertiles n. ≤240m =510; 241-396m =505; >396m =505. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplemental Table 5. Characteristics of the study population by 6MWT changes between baseline 
and 9 months 
6MWT (m) Decrease (≤0 m) Increase (>0 m) p-value 
N. 472 1247  
Age (years) 68.7 ± 11.2 66.8 ± 12.1 0.003 
Male sex 364 (77.1%) 919 (73.7%) 0.15 
BMI (Kg/m2) 27.8 ± 5.1 28.1 ± 5.5 0.37 
Heart rate (bpm) 77.0 ± 18.8 83.2 ± 21.7 <0.001 
SBP (mmHg) 126.0 ± 20.2 125.2 ± 21.8 0.46 
Pulmonary rales 196 (43.0%) 639 (52.6%) <0.001 
Peripheral edema 208 (52.5%) 585 (56.0%) 0.23 
Elevated JVP 78 (23.4%) 274 (30.5%) 0.014 
NYHA class III/IV 254 (54.6%) 738 (60.5%) 0.027 
Orthopnea  118 (25.1%) 430 (34.5%) <0.001 
LVEF (%) 31.5 ± 9.9 30.3 ± 10.1 0.043 
Ischemic HF 220 (46.6%) 512 (41.1%) 0.038 
HFH in the last 12 months 185 (39.2%) 333 (26.7%) <0.001 
Atrial fibrillation 229 (48.5%) 508 (40.7%) 0.004 
Previous stroke 40 (8.5%) 114 (9.1%) 0.67 
Peripheral arterial disease 45 (9.5%) 116 (9.3%) 0.88 
Hypertension 331 (70.1%) 746 (59.8%) <0.001 
Device therapy 129 (27.3%) 275 (22.1%) 0.021 
Current smoking 59 (12.5%) 186 (14.9%) 0.40 
Diabetes 166 (35.2%) 368 (29.5%) 0.024 
COPD 76 (16.1%) 209 (16.8%) 0.74 
Current malignancy 13 (2.8%) 45 (3.6%) 0.38 
Hemoglobin (g/dL) 13.2 ± 1.7 13.4 ± 1.8 0.026 
eGFR (ml/min/1.73m2) 63.5 ± 22.6 65.4 ± 22.9 0.14 
Urea (mmol/L) 14.4 ± 9.3 13.4 ± 11.0 0.13 
Sodium (mmol/L) 139.5 ± 3.6 139.3 ± 3.6 0.40 
Potassium (mmol/L) 4.2 ± 0.5 4.2 ± 0.5 0.16 
Glucose (mmol/L) 7.1 ± 3.2 7.0 ± 2.8 0.76 
Total Cholesterol (mmol/L) 4.3 ± 1.2 4.4 ± 1.3 0.27 
HDL cholesterol (mmol/L)  1.1 ± 0.3 1.1 ± 0.3 0.83 
NT-pro BNP (NPX) 2.8 ± 1.2 2.8 ± 1.3 0.56 
logTnI, mean ± SD 1.0 ± 0.5 1.1 ± 0.5 0.005 
MRA 267 (56.6%) 663 (53.2%) 0.21 
Loop Diuretics 472 (100.0%) 1241 (99.5%) 0.13 
Digoxin 93 (19.7%) 244 (19.6%) 0.95 
Beta-blocker  400 (84.7%) 1069 (85.7%) 0.61 
Beta-blocker >=50% at 3 mo. 199 (42.2%) 462 (37.0%) 0.052 
ACE/ARB  357 (75.6%) 935 (75.0%) 0.78 
ACE/ARB >=50% at 3 mo. 266 (56.4%) 705 (56.5%) 0.95 
Delta 6MWT (m) -104.7 ± 108.6 130.0 ± 148.4 <0.001 
Legend: BMI, body mass index; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting; HFH, heart failure hospitalization; COPD, chronic 
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; 
ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 6. Logistic regression for 6MWT increase from baseline to 9 months 
Variable OR (95%CI) for 6MWT increase p-value 
Age (per 10 yr) 0.68 (0.60-0.77) <0.001 
Diabetes  0.58 (0.44-0.76) <0.001 
NT-proBNP (per NPX doubling) 0.89 (0.81-0.99) 0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1. Baseline 6MWT distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2. Delta 6MWT distribution 
 
Adjusted delta = 6MWT distance at month 9 minus 6MWT distance at baseline adjusted on the baseline 6MWT distance 
value. 
